- Home
- CR vs PCVX Comparison
CR vs PCVX Comparison
Compare CR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | PCVX |
|---|---|---|
| Founded | 1855 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 7.0B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CR | PCVX |
|---|---|---|
| Price | $187.86 | $47.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $226.20 | $88.25 |
| AVG Volume (30 Days) | 444.3K | ★ 1.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 23.96 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $2,305,000,000.00 | N/A |
| Revenue This Year | $27.98 | N/A |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | $165.55 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $159.58 | $29.10 |
| 52 Week High | $214.31 | $65.00 |
Technical Indicators
Market Signals| Indicator | CR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 37.91 |
| Support Level | $183.02 | $41.52 |
| Resistance Level | $197.20 | $49.46 |
| Average True Range (ATR) | 5.30 | 2.06 |
| MACD | 1.38 | 0.01 |
| Stochastic Oscillator | 85.67 | 15.81 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.